Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study

Bone Marrow Transplantation
M WilhelmssonNordic Society of Pediatric Hematology and Oncology (NOPHO)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves event-free survival in acute myeloid leukemia (AML); however, the burden of late effects may be increased. We compared health-related outcomes in childhood AML survivors treated according to the NOPHO-AML protocols either with or without allo-HSCT at age < 21 years. Out of the 147 eligible AML survivors treated with allo-HSCT, 95 (65%) and 53 (75%) of their eligible siblings completed a questionnaire. Their data were compared to corresponding data collected previously from NOPHO-AML survivors treated with chemotherapy only (CT) (n = 101). The median follow-up was 12 (range 2-28) years after allo-HSCT and 47% had received total body irradiation (TBI)-based conditioning. Allo-HSCT survivors reported significantly more physical health limitations (39% vs 7%, p < 0.005), medications for cardiovascular disease (10% vs 1%, p < 0.05) and use of analgesics (32% vs 11%, p < 0.01) than CT survivors. Health problems prevented 16% of the allo-HSCT survivors from attending school or managing a job vs. 3% among CT survivors (p < 0.05). Among 73 allo-HSCT survivors (age ≥ 15 years), seven females reported natural pregnancies and three males reported unassisted conceptions...Continue Reading

References

Dec 1, 1988·The New England Journal of Medicine·I Hertz-Picciotto, S J Samuels
May 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J LiesnerJ M Chessells
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W LeungC H Pui
Aug 11, 2001·Lancet·N SaloojaUNKNOWN Late Effects Working Party of the European Group for Blood and Marrow Transplantation
Apr 30, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephanie J LeeMary E D Flowers
Feb 6, 2007·British Journal of Haematology·Jonas AbrahamssonUNKNOWN Nordic Society for Paediatric Haematology and Oncology (NOPHO)
Jul 24, 2008·Bone Marrow Transplantation·K Vettenranta, UNKNOWN EBMT Paediatric Working Party
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saro H ArmenianSmita Bhatia
Oct 22, 2008·Bone Marrow Transplantation·C M LöfU Forinder
Oct 31, 2008·Blood·J Douglas RizzoH Joachim Deeg
Sep 1, 2009·Bone Marrow Transplantation·L HoviU M Saarinen-Pihkala
Sep 1, 2009·Bone Marrow Transplantation·J E SandersK L Syrjala
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·India Y SislerHaydar A Frangoul
Mar 18, 2010·International Journal of Pediatric Obesity : IJPO : an Official Journal of the International Association for the Study of Obesity·M de Onis, T Lobstein
Apr 12, 2011·Bone Marrow Transplantation·A Borgmann-StaudtG Strauss
Nov 19, 2011·Pediatric Blood & Cancer·Lene Molgaard-HansenUNKNOWN Nordic Society of Pediatric Hematology and Oncology
Jun 22, 2013·BMC Geriatrics·Kim BouillonG David Batty
Sep 17, 2013·Pediatric Blood & Cancer·Lene Molgaard-HansenUNKNOWN Nordic Society of Pediatric Hematology and Oncology
Apr 25, 2014·Pediatric Blood & Cancer·Anne-Sofie SkouUNKNOWN Nordic Society of Pediatric Hematology and Oncology
Mar 11, 2015·The Lancet Oncology·Saro H ArmenianUNKNOWN International Late Effects of Childhood Cancer Guideline Harmonization Group
Mar 31, 2015·Bone Marrow Transplantation·Y InamotoN S Majhail
Apr 30, 2017·Expert Review of Quality of Life in Cancer Care·Kirsten K NessKari L Bjornard
Mar 28, 2018·Bone Marrow Transplantation·Christine N DuncanK Scott Baker

❮ Previous
Next ❯

Citations

Sep 6, 2019·European Journal of Pediatrics·Sophie L'excellentVéronique Houdouin
Feb 9, 2020·International Journal of Immunogenetics·Alexander H SchmidtJohannes Schetelig
Apr 1, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Iryna KolosenkoCaroline Palm-Apergi
May 23, 2021·Pediatric Blood & Cancer·Anne Sophie Lind HelligsoeHenrik Hasle
Dec 11, 2021·Hematology·David Buchbinder, Nandita Khera

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.